AZTA icon

Azenta
AZTA

Upgrade to unlock
Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 88.9%
Negative

Neutral
PRNewsWire
12 days ago
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026.
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
Negative
Seeking Alpha
26 days ago
Azenta: Life Science Player Fails To Come To Life
Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income.
Azenta: Life Science Player Fails To Come To Life
Neutral
Seeking Alpha
1 month ago
Azenta, Inc. (AZTA) M&A Call Transcript
Azenta, Inc. (AZTA) M&A Call Transcript
Azenta, Inc. (AZTA) M&A Call Transcript
Neutral
PRNewsWire
1 month ago
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom.
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
Neutral
PRNewsWire
1 month ago
Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET.
Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
Neutral
PRNewsWire
2 months ago
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space.
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
Neutral
Seeking Alpha
2 months ago
Azenta, Inc. (AZTA) Q1 2026 Earnings Call Transcript
Azenta, Inc. (AZTA) Q1 2026 Earnings Call Transcript
Azenta, Inc. (AZTA) Q1 2026 Earnings Call Transcript
Neutral
PRNewsWire
2 months ago
Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025
BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025.
Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025
Neutral
PRNewsWire
2 months ago
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens.
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
Negative
Zacks Investment Research
3 months ago
New Strong Sell Stocks for January 8th
AZTA, BCBP and CLCO have been added to the Zacks Rank #5 (Strong Sell) List on January 8th, 2026.
New Strong Sell Stocks for January 8th
See News Rankings